Header Logo

Connection

MEHMET OKCU to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications MEHMET OKCU has written about Cost-Benefit Analysis.
MEHMET OKCU
Connection Strength
0.039
Cost-Benefit Analysis
  1. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2022 Jan 15; 128(2):317-325.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.